Compare
AbbVie vs Exelixis (ABBV vs EXEL)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Exelixis (EXEL) +72.3%; so far this year the figures are +27.5% and +58.7%.
AbbVie is the larger company by market value, about 30.3 times the size of Exelixis.
On trailing earnings, ABBV trades at 50.1 times and EXEL at 20.8 times.
Revenue grew +10.7% at ABBV and +9.1% at EXEL over the last year.
ABBV yields 2.38%. EXEL pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | EXEL | |
|---|---|---|
| Price | $291.31 | $69.57 |
| 1-day | +1.07% | +1.25% |
| YTD | +27.49% | +58.73% |
| 1 year | +34.39% | +72.33% |
| 3 years | +104.47% | +230.97% |
| Market cap | $514.9B | $17.0B |
| P/E | 50.1 | 20.8 |
| P/S | 7.80 | 6.80 |
| P/B | — | 9.26 |
| Revenue growth | +10.70% | +9.10% |
| EPS growth | +340.20% | +40.90% |
| Gross margin % | 73.7 | 96.3 |
| Net margin % | 15.7 | 35.5 |
| ROE % | — | 48.3 |
| Debt / equity | — | 0.10 |
| FCF yield % | 3.7 | 6.8 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.61 |
| RSI (14) | 59.7 | 66.0 |
| Technical rating |